Brief: NexImmune Reports IND Clearance by FDA for NEXI-003
14/07/2022 21:36
July 14 (Reuters) - Neximmune Inc NEXI.O :
* NEXIMMUNE ANNOUNCES IND CLEARANCE BY US FDA FOR NEXI-003
FOR
TREATMENT OF HPV-RELATED CANCERS
* NEXIMMUNE INC - IND CLEARANCE ENABLES COMMENCEMENT OF A
CLINICAL
TRIAL TO EVALUATE NEXI-003
* NEXIMMUNE INC - PHASE 1 TRIAL WILL ENROLL PATIENTS AT
MULTIPLE
CLINICAL SITES ACROSS UNITED STATES
* NEXIMMUNE INC - PLANS TO EXPAND NEXI-003 DEVELOPMENT
PROGRAM TO
INCLUDE OTHER HPV RELATED MALIGNANCIES
Source text for Eikon: ID:nGNX6xkkg0
Further company coverage: NEXI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neximmune
See all newsBrief: Neximmune Appointed Albert Marchio As Interim CFO
Brief: NexImmune and Agents Agreed To Terminate Sales Agreement & ATM Program dated June 2022
Brief: NexImmune Says Co Expects Existing Cash And Cash Equivalents Will Be Sufficient To Meet Its Anticipated Cash Requirements Through Mid-February 2024
Brief: Neximmune Gets Notice From Listing Qualifications Department Of Nasdaq
Brief: NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting